Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Yet one of the company's most promising candidates, weight management medicine MariTide, failed to produce the kinds of results the market wanted in a phase 2 clinical trial, and the stock fell. Even ...

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent ...